Department of Genetics, Harvard Medical School, Boston, MA, USA; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
Department of Genetics, Harvard Medical School, Boston, MA, USA; Department of Pharmacology, The University of New South Wales, Sydney, Australia.
Mech Ageing Dev. 2019 Jun;180:117-128. doi: 10.1016/j.mad.2019.03.007. Epub 2019 Apr 17.
Even though they would have great benefit across research and clinical fields, currently there are no accepted biomarkers of frailty. Cross-sectional studies in humans have identified promising candidates including inflammatory markers such as IL-6, immune markers such as WBC count, clinical markers such as albumin, endocrine markers such as vitamin D, oxidative stress markers such as isoprostanes, proteins such as BDNF and epigenetic markers such as DNA methylation, but there are limitations to the current state of the research. Future approaches to the identification of frailty biomarkers should include longitudinal studies, studies using animal models of frailty, studies incorporating novel biomarkers combined into composite panels, and studies investigating sex differences and potential overlap between markers of biological age and frailty.
尽管在研究和临床领域具有重要意义,但目前尚无公认的衰弱生物标志物。人体横断面研究已经确定了一些有前途的候选标志物,包括炎症标志物(如 IL-6)、免疫标志物(如白细胞计数)、临床标志物(如白蛋白)、内分泌标志物(如维生素 D)、氧化应激标志物(如异前列烷)、蛋白质标志物(如 BDNF)和表观遗传标志物(如 DNA 甲基化),但目前的研究还存在局限性。未来鉴定衰弱生物标志物的方法应包括纵向研究、使用衰弱动物模型的研究、将新型生物标志物组合成综合指标的研究,以及研究性别差异和生物年龄标志物与衰弱之间的潜在重叠的研究。